JP2024525998A5 - - Google Patents
Info
- Publication number
- JP2024525998A5 JP2024525998A5 JP2023570055A JP2023570055A JP2024525998A5 JP 2024525998 A5 JP2024525998 A5 JP 2024525998A5 JP 2023570055 A JP2023570055 A JP 2023570055A JP 2023570055 A JP2023570055 A JP 2023570055A JP 2024525998 A5 JP2024525998 A5 JP 2024525998A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- cerebral infarction
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021079820 | 2021-05-10 | ||
| JP2021079820 | 2021-05-10 | ||
| PCT/US2022/028488 WO2022240810A1 (en) | 2021-05-10 | 2022-05-10 | Pharmaceutical composition for use in treating cerebral infarction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525998A JP2024525998A (ja) | 2024-07-16 |
| JP2024525998A5 true JP2024525998A5 (enExample) | 2025-04-30 |
Family
ID=82214306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570055A Pending JP2024525998A (ja) | 2021-05-10 | 2022-05-10 | 脳梗塞治療用医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240238248A1 (enExample) |
| EP (1) | EP4337193A1 (enExample) |
| JP (1) | JP2024525998A (enExample) |
| KR (1) | KR20240005749A (enExample) |
| CN (1) | CN117295497A (enExample) |
| AU (1) | AU2022275263A1 (enExample) |
| BR (1) | BR112023023534A2 (enExample) |
| CA (1) | CA3216137A1 (enExample) |
| WO (1) | WO2022240810A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022226013A1 (en) * | 2021-04-20 | 2022-10-27 | Biogen Ma Inc. | Pharmaceutical composition comprising the compound smtp-7 |
| WO2026092761A1 (zh) * | 2024-11-04 | 2026-05-07 | 江苏恒瑞医药股份有限公司 | 包含smtp衍生物的药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004224737A (ja) * | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| JP4313049B2 (ja) | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| KR20080112184A (ko) | 2006-03-27 | 2008-12-24 | 노우코우다이 티엘오 가부시키가이샤 | 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제 |
| JP5605659B2 (ja) * | 2009-07-06 | 2014-10-15 | 国立大学法人東京農工大学 | 細胞保護剤 |
| JP7381035B2 (ja) * | 2018-11-02 | 2023-11-15 | 学校法人昭和大学 | Ｓｍｔｐ一群又はｓｍｔｐ－７の製造中間体及びその化学的製造方法 |
| CN121064221A (zh) * | 2021-02-10 | 2025-12-05 | 福建盛迪医药有限公司 | 一种smtp-7衍生物及其用途 |
| WO2022226013A1 (en) * | 2021-04-20 | 2022-10-27 | Biogen Ma Inc. | Pharmaceutical composition comprising the compound smtp-7 |
-
2022
- 2022-05-10 US US18/289,399 patent/US20240238248A1/en active Pending
- 2022-05-10 AU AU2022275263A patent/AU2022275263A1/en active Pending
- 2022-05-10 CN CN202280033982.7A patent/CN117295497A/zh active Pending
- 2022-05-10 BR BR112023023534A patent/BR112023023534A2/pt unknown
- 2022-05-10 CA CA3216137A patent/CA3216137A1/en active Pending
- 2022-05-10 JP JP2023570055A patent/JP2024525998A/ja active Pending
- 2022-05-10 WO PCT/US2022/028488 patent/WO2022240810A1/en not_active Ceased
- 2022-05-10 KR KR1020237038570A patent/KR20240005749A/ko active Pending
- 2022-05-10 EP EP22733771.4A patent/EP4337193A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McCormack | Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis | |
| Bevers et al. | Critical care management of acute ischemic stroke | |
| Gami et al. | Contrast nephropathy after coronary angiography | |
| JP6795571B2 (ja) | グリブリドおよび他の薬剤の静脈内投与方法 | |
| Hattenbach et al. | Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion | |
| Kearns et al. | Neuroprotective therapies for spontaneous intracerebral hemorrhage | |
| EA010134B1 (ru) | Фармацевтические препараты, способы и схемы приема для лечения и предупреждения острых коронарных синдромов | |
| Chugh et al. | Cerebral vasospasm and delayed cerebral ischemia: Review of literature and the management approach | |
| EA019258B1 (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ | |
| JP7835735B2 (ja) | シクロデキストリンによるコレステロール結晶塞栓症の治療方法 | |
| Fulgham et al. | Management of acute ischemic stroke | |
| Almoosa | Is thrombolytic therapy effective for pulmonary embolism? | |
| Tebbe et al. | Desmoteplase in acute massive pulmonary thromboembolism | |
| KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
| KR102008826B1 (ko) | 나토키나제와 항염증제를 유효성분으로 포함하는 혈소판 응집 억제용 또는 혈전용해용 의약 조성물 | |
| US20090285909A1 (en) | Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof | |
| JP2024525998A (ja) | 脳梗塞治療用医薬組成物 | |
| JP2024525239A (ja) | 化合物ｓｍｔｐ－７を含有する医薬組成物 | |
| TW201119655A (en) | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients | |
| Doornaert et al. | Extravasation injuries: current medical and surgical treatment | |
| US20230330192A1 (en) | Methods of using polymerized human serum albumin | |
| Dalal | Ischaemic strokes: Management in first six hours | |
| CN115715221A (zh) | 用于治疗或预防多器官功能障碍综合征的组合物和方法 | |
| Karmakar et al. | Neuroprotection in subarachnoid hemorrhage | |
| Barik et al. | Controversies in the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage |